Ignite Creation Date:
2024-05-06 @ 5:27 PM
Last Modification Date:
2024-10-26 @ 2:29 PM
Study NCT ID:
NCT05319873
Status:
RECRUITING
Last Update Posted:
2024-04-18
First Post:
2022-03-18
Brief Title:
Ribociclib Tucatinib and Trastuzumab for the Treatment of HER2 Positive Breast Cancer
Sponsor:
Jonsson Comprehensive Cancer Center
Organization:
Jonsson Comprehensive Cancer Center
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Anatomic Stage II Breast Cancer AJCC v8 |
| Anatomic Stage IIA Breast Cancer AJCC v8 |
| Anatomic Stage IIB Breast Cancer AJCC v8 |
| Anatomic Stage III Breast Cancer AJCC v8 |
| Anatomic Stage IIIA Breast Cancer AJCC v8 |
| Anatomic Stage IIIB Breast Cancer AJCC v8 |
| Anatomic Stage IIIC Breast Cancer AJCC v8 |
| Anatomic Stage IV Breast Cancer AJCC v8 |
| Invasive Breast Carcinoma |
| Locally Advanced HER2-Positive Breast Carcinoma |
| Metastatic HER2-Positive Breast Carcinoma |
| Prognostic Stage IB Breast Cancer AJCC v8 |
| Prognostic Stage II Breast Cancer AJCC v8 |
| Prognostic Stage IIA Breast Cancer AJCC v8 |
| Prognostic Stage IIB Breast Cancer AJCC v8 |
| Prognostic Stage III Breast Cancer AJCC v8 |
| Prognostic Stage IIIA Breast Cancer AJCC v8 |
| Prognostic Stage IIIB Breast Cancer AJCC v8 |
| Prognostic Stage IIIC Breast Cancer AJCC v8 |
| Prognostic Stage IV Breast Cancer AJCC v8 |
Keywords: